NCT05630365 is a NA clinical trial of Panbio™ in COVID-19, sponsored by Abbott Rapid Dx.

Who is sponsoring NCT05630365?

NCT05630365 is sponsored by Abbott Rapid Dx.

What drugs are being tested in NCT05630365?

Interventions in NCT05630365: Panbio™.

What condition does NCT05630365 study?

NCT05630365 studies COVID-19, Influenza A, Influenza Type B.

Is NCT05630365 still recruiting?

NCT05630365 is currently completed. Last updated 9 November 2023.

Last reviewed 2023-11-09 · How we verify

NCT05630365

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Product Using Mid-Turbinate Nasal Swabs

Completed NA Last updated 9 November 2023

What this trial tests

NA trial testing Panbio™ in COVID-19 in 1,129 participants. Completed in 31 March 2023.

Timeline

15 December 2022

Primary endpoint
31 March 2023

31 March 2023

Quick facts

Lead sponsor	Abbott Rapid Dx
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	1,129
Start date	15 December 2022
Primary completion	31 March 2023
Estimated completion	31 March 2023
Sites	1 location across United States

Drugs / interventions tested

Panbio™

Conditions studied

COVID-19 — all drugs for COVID-19 →
Influenza A — all drugs for Influenza A →
Influenza Type B — all drugs for Influenza Type B →

Sponsor

Abbott Rapid Dx

Who can join

Eligibility, any sex, with COVID-19 or Influenza A. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed as an international, prospective, multicentric, clinical study to investigate the performance of the Panbio™ COVID-19/Flu A\&B Rapid Panel for the qualitative detection of COVID-19 antigen, Influenza A antigen, and Influenza B antigen in human mid-turbinate nasal swabs collected by a trained health worker. This study is part of the performance evaluation to support the CE conformity assessment procedures.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

SARS-CoV-2 versus Influenza A Virus: Characteristics and Co-Treatments.
Wang X, Li J, Liu H, Hu X, et al · · 2023 · cited 7× · PMID 36985154 · DOI 10.3390/microorganisms11030580

Verify or expand the search:

Other trials of Panbio™

Trials testing the same drug.

NCT06127108 — Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel · NA · completed
NCT05715515 — Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Device and the Panbio™ COVID-19/Flu A&B · NA · completed

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Abbott Rapid Dx trials

Trials by the same sponsor.

NCT07203183 — Dengue - Sample Collection Study Pakistan · not yet recruiting
NCT06928129 — Clinical Feasibility of the BinaxNOW™ COVID-19/Flu A&B Combo in the Southern Hemisphere · NA · not yet recruiting
NCT06492018 — Lay User Evaluation of the Panbio™ HCV Self Test in an EU Population · not yet recruiting
NCT06395675 — Clinical Evaluation of the ID NOW™ CT/NG Test · NA · not yet recruiting
NCT06124638 — Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel to Support Home Use · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05630365 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abbott Rapid Dx
Last refreshed: 9 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05630365.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing